Atara Biotherapeutics Inc. (NASDAQ:ATRA) traded with a subtraction of -$0.13 to $3.46 on Thursday, a downside of -3.48 percent. An average of 2,184,935 shares of common stock have been traded in the last five days. There was a fall of -$1.29 in the past week, and it reached a new high 6 times over the past 12 months. The last 20 days have seen an average of 1,825,154 shares traded, while the 50-day average volume stands at 2,668,681.
ATRA stock has decreased by -14.11% in the last month. The company shares reached their 1-month lowest point of $3.40 on 09/22/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $2.83 and a high of $20.04 in 52 weeks. It has reached a new high 1 time so far this year and lost -77.22% or -$12.36 in price. In spite of this, the price is down -82.71% from the 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
37 days have passed since Atara Biotherapeutics Inc. (ATRA) last reported insider trading activity. Touchon Pascal, who is President and CEO, most recently acquired $14,806 shares at $5.04 per share on Aug 16. In this transaction, the insider spent $74,548. EVP, Head of R&D, Dupont Jakob, disposed of 4,124 shares at a price of $5.03 on Aug 16. The insider now owns more than $20,760 worth of shares. Prior to that, SVP, GC & Secretary Murugan Amar went on to Sale 3,430 shares at $5.03 each on Aug 16. An amount of $17,269 was transacted.
Atara Biotherapeutics Inc. (ATRA) stock’s beta is 0.92. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 5.49, the price-to-book (PB) ratio at 1.42.
The quick ratio of Atara Biotherapeutics Inc. for the three months ended June 29 was 5.30, and the current ratio was 5.30, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $360.8 million compared to revenue of $20.34 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Atara Biotherapeutics Inc.’s return on assets was -56.60%.
For the three-month period that ended June 29, Atara Biotherapeutics Inc. had $260.62 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $18.47 million in the quarter, while revenues of -$88.11 million were grew 553.65%. The analyst consensus anticipated Atara Biotherapeutics Inc.’s latest quarter earnings to come in at -$0.93 per share, but it turned out to be $0.18, a 119.40% surprise. For the quarter, EBITDA amounted to -$30.38 million. Shareholders own equity worth $94.36 million.
From a technical analysis perspective, let’s take a brief look at Atara Biotherapeutics Inc. (ATRA) price momentum. RSI 9-day as of the close on 21 September was 26.81%, suggesting the stock is oversold, with historical volatility in this time frame at 77.89%.
As of today, ATRA’s price is $3.73 -27.55% or -$1.29 from its 5-day moving average. ATRA is currently trading -25.98% lower than its 20-day SMA and -46.46% lower than its 100-day SMA. However, the stock’s current price level is -12.47% below the SMA50 and -79.95% below the SMA200.
The stochastic %K and %D were 4.41% and 8.86%, respectively, and the average true range (ATR) was 0.34. With the 14-day stochastic at 0.31% and the average true range at 0.37, the RSI (14) stands at 35.08%. The stock has reached -0.57 on the 9-day MACD Oscillator while the 14-day reading was at -0.70.
Citigroup downgraded Atara Biotherapeutics Inc. (NASDAQ: ATRA) to a a Sell rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Atara Biotherapeutics Inc. (ATRA) among analysts is Overweight. According to current brokerage recommendations, 2 brokerage firms advise that investors sell ATRA, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 6 others rate it as a “buy”.